Advertisement

Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis

  • Lawrence A. Ho
  • Ganesh Raghu
Chapter

Abstract

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic and progressive fibrosing interstitial pneumonia of unknown cause. IPF is the most common form of idiopathic interstitial pneumonia (IIP) and accounts for 50–60% of these diseases. Even though the cause of IPF is unknown, various exposures such cigarette smoking, metal/wood dust, certain drugs and importantly gastroesophageal reflux (GER) have been associated with IPF. There is an increasing body of literature regarding the relationship between GER and IPF, particularly over the last decade. This has culminated in anti-acid medications receiving a conditional recommendation for use in patients with IPF in the most recent American Thoracic Society/European Respiratory Society/Japanese Respiratory Society and Latin American Thoracic Associate guidelines for the treatment of IPF. This chapter will explore the proposed pathologic relationship between IPF and GER as well as treatments, outcomes and future directions.

References

  1. 1.
    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64.Google Scholar
  3. 3.
    Raghu G, Chen S-Y, Hou Q, Yeh W-S, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J. 2016;48(1):179–86.CrossRefPubMedGoogle Scholar
  4. 4.
    King TEJ, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.CrossRefPubMedGoogle Scholar
  7. 7.
    Hunninghake GW, Schwarz MI. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis?: a perspective. Proc Am Thorac Soc. 2007;4(5):449–52.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155(1):242–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Stewart JP, Egan JJ, Ross AJ, Kelly BG, Lok SS, Hasleton PS, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1336–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Noth I, Zhang Y, Ma S-F, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309–17.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Pearson JE, Wilson RS. Diffuse pulmonary fibrosis and hiatus hernia. Thorax. 1971;26(3):300–5.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Noth I, Zangan SM, Soares RV, Forsythe A, Demchuk C, Takahashi SM, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):344–51.CrossRefPubMedGoogle Scholar
  13. 13.
    el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997;113(3):755–60.CrossRefPubMedGoogle Scholar
  14. 14.
    Tcherakian C, Cottin V, Brillet P-Y, Freynet O, Naggara N, Carton Z, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax. 2011;66(3):226–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Mays EE, Dubois JJ, Hamilton GB. Pulmonary fibrosis associated with tracheobronchial aspiration. A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest. 1976;69(4):512–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Tobin RW, Pope CE, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(6):1804–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Salvioli B, Belmonte G, Stanghellini V, Baldi E, Fasano L, Pacilli AMG, et al. Gastro-oesophageal reflux and interstitial lung disease. Dig Liver Dis. 2006;38(12):879–84.CrossRefPubMedGoogle Scholar
  19. 19.
    Sweet MP, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg. 2007;133(4):1078–84.CrossRefPubMedGoogle Scholar
  20. 20.
    Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J. 2012;39(2):242.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010;123(4):304–11.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mitsuhashi T, Shimazaki M, Chanoki Y, Kuwahara H, Sakai T, Masuda H. Experimental pulmonary fibrosis induced by trisodium citrate and acid-citrate-dextrose. Exp Mol Pathol. 1985;42(2):261–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Schwartz DJ, Wynne JW, Gibbs CP, Hood CI, Kuck EJ. The pulmonary consequences of aspiration of gastric contents at pH values greater than 2.5. Am Rev Respir Dis. 1980;121(1):119–26.PubMedGoogle Scholar
  24. 24.
    Popper H, Juettner F, Pinter J. The gastric juice aspiration syndrome (Mendelson syndrome). Aspects of pathogenesis and treatment in the pig. Virchows Arch A Pathol Anat Histopathol. 1986;409(1):105–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Appel JZ, Lee SM, Hartwig MG, Li B, Hsieh C-C, Cantu E, et al. Characterization of the innate immune response to chronic aspiration in a novel rodent model. Respir Res. 2007;8(1):87.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Perng D-W, Chang K-T, Su K-C, Wu Y-C, Wu M-T, Hsu W-H, et al. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-β1 production and fibroblast proliferation. Chest. 2007;132(5):1548–56.CrossRefPubMedGoogle Scholar
  27. 27.
    Blondeau K, Mertens V, Vanaudenaerde BA, Verleden GM, Van Raemdonck DE, Sifrim D, et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J. 2008;31(4):707.CrossRefPubMedGoogle Scholar
  28. 28.
    D’Ovidio F, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg. 2005;129(5):1144–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390–4.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Allaix ME, Fisichella PM, Noth I, Herbella FA, Borraez Segura B, Patti MG. Idiopathic pulmonary fibrosis and gastroesophageal reflux. Implications for treatment. J Gastrointest Surg. 2014;18(1):100–4. Discussion 104-5.CrossRefPubMedGoogle Scholar
  31. 31.
    Savarino E, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42(5):1322–31.CrossRefPubMedGoogle Scholar
  32. 32.
    Gavini S, Borges LF, Finn RT, Lo W-K, Goldberg HJ, Burakoff R, et al. Lung disease severity in idiopathic pulmonary fibrosis is more strongly associated with impedance measures of bolus reflux than pH parameters of acid reflux alone. Neurogastroenterol Motil. 2017;29(5):e13001.CrossRefGoogle Scholar
  33. 33.
    Johnston N, Wells CW, Blumin JH, Toohill RJ, Merati AL. Receptor-mediated uptake of pepsin by laryngeal epithelial cells. Ann Otol Rhinol Laryngol. 2007;116(12):934–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Bathoorn E, Daly P, Gaiser B, Sternad K, Poland C, MacNee W, et al. Cytotoxicity and induction of inflammation by pepsin in acid in bronchial epithelial cells. Int J Inflamm. 2011;2011:5.CrossRefGoogle Scholar
  35. 35.
    Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–75.CrossRefPubMedGoogle Scholar
  36. 36.
    Lee JS, Song JW, Wolters PJ, Elicker BM, King TE, Kim DS, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Raghu G, Yang ST-Y, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129(3):794–800.CrossRefPubMedGoogle Scholar
  38. 38.
    Linden PA, Gilbert RJ, Yeap BY, Boyle K, Deykin A, Jaklitsch MT, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg. 2006;131(2):438–46.CrossRefPubMedGoogle Scholar
  39. 39.
    Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54(11):2312–7.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81.CrossRefPubMedGoogle Scholar
  41. 41.
    Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther. 2009;331(1):255–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;509(2–3):201–10.CrossRefPubMedGoogle Scholar
  43. 43.
    Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med. 2015;13:249.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med. 2016;193(12):1345–52.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, et al. Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis who received pirfenidone. Respiration. 2017;93:415.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Raghu G. Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution. Lancet Respir Med. 2016;4(9):e46–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Johnson WC, Raghu G. Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures. Eur Respir J. 2005;26(5):755–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Dallemagne B, Weerts J, Markiewicz S, Dewandre J-M, Wahlen C, Monami B, et al. Clinical results of laparoscopic fundoplication at ten years after surgery. Surg Endosc. 2006;20(1):159–65.CrossRefPubMedGoogle Scholar
  49. 49.
    Pellegrini CA, DeMeester TR, Johnson LF, Skinner DB. Gastroesophageal reflux and pulmonary aspiration: incidence, functional abnormality, and results of surgical therapy. Surgery. 1979;86(1):110–9.PubMedGoogle Scholar
  50. 50.
    Patti MG, Arcerito M, Tamburini A, Diener U, Feo CV, Safadi B, et al. Effect of laparoscopic fundoplication on gastroesophageal reflux disease-induced respiratory symptoms. J Gastrointest Surg. 2000;4(2):143–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Ciovica R, Gadenstatter M, Klingler A, Neumayer C, Schwab GP. Laparoscopic antireflux surgery provides excellent results and quality of life in gastroesophageal reflux disease patients with respiratory symptoms. J Gastrointest Surg. 2005;9(5):633–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Raghu G, Morrow E, Collins BF, Ho LAT, Hinojosa MW, Hayes JM, et al. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. Eur Respir J. 2016;48(3):826–32.CrossRefPubMedGoogle Scholar
  53. 53.
    Johannson KA, Strambu I, Ravaglia C. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers. Lancet Respir Med. 2017;5:591.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations